Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation

Clin Microbiol Rev. 2020 Oct 28;34(1):e00043-19. doi: 10.1128/CMR.00043-19. Print 2020 Dec 16.


Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS, transplant recipients, and fetuses, are at the highest risk for complications from cytomegalovirus (CMV) infection. Despite substantial progress in prevention, diagnostics, and treatment, CMV continues to negatively impact both solid-organ transplant (SOT) and hematologic cell transplant (HCT) recipients. In this article, we summarize important developments in the field over the past 10 years and highlight new approaches and remaining challenges to the optimal control of CMV infection and disease in transplant settings.

Keywords: antiviral agents; clinical trials; cytomegalovirus; diagnostics; immune monitoring; immunocompromised hosts; transplant infectious diseases; transplantation; vaccines.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Clinical Trials as Topic
  • Cytomegalovirus Infections / diagnosis*
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / prevention & control*
  • Early Diagnosis
  • Humans
  • Immunocompromised Host
  • Organ Transplantation / adverse effects*


  • Antiviral Agents